These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
172 related articles for article (PubMed ID: 29369798)
1. Prognostic Role of BRAF Abd Elmageed ZY; Moore RF; Tsumagari K; Lee MM; Sholl AB; Friedlander P; Al-Qurayshi Z; Hassan M; Wang AR; Boulares HA; Kandil E J Am Coll Surg; 2018 Apr; 226(4):526-537. PubMed ID: 29369798 [TBL] [Abstract][Full Text] [Related]
2. Impact of MET expression on outcome in BRAF(V600E/K) advanced melanoma. Jubb AM; Ribas A; Sosman JA; McArthur GA; Yan Y; Rost S; Zhao S; Koeppen H Histopathology; 2013 Sep; 63(3):351-61. PubMed ID: 23802768 [TBL] [Abstract][Full Text] [Related]
3. Vemurafenib in patients with BRAF V600E mutation-positive advanced melanoma. Ravnan MC; Matalka MS Clin Ther; 2012 Jul; 34(7):1474-86. PubMed ID: 22742884 [TBL] [Abstract][Full Text] [Related]
4. Immunohistochemistry is highly sensitive and specific for the detection of V600E BRAF mutation in melanoma. Long GV; Wilmott JS; Capper D; Preusser M; Zhang YE; Thompson JF; Kefford RF; von Deimling A; Scolyer RA Am J Surg Pathol; 2013 Jan; 37(1):61-5. PubMed ID: 23026937 [TBL] [Abstract][Full Text] [Related]
16. Resveratrol Overcomes Cellular Resistance to Vemurafenib Through Dephosphorylation of AKT in BRAF-mutated Melanoma Cells. Luo H; Umebayashi M; Doi K; Morisaki T; Shirasawa S; Tsunoda T Anticancer Res; 2016 Jul; 36(7):3585-9. PubMed ID: 27354627 [TBL] [Abstract][Full Text] [Related]
17. Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma. Trunzer K; Pavlick AC; Schuchter L; Gonzalez R; McArthur GA; Hutson TE; Moschos SJ; Flaherty KT; Kim KB; Weber JS; Hersey P; Long GV; Lawrence D; Ott PA; Amaravadi RK; Lewis KD; Puzanov I; Lo RS; Koehler A; Kockx M; Spleiss O; Schell-Steven A; Gilbert HN; Cockey L; Bollag G; Lee RJ; Joe AK; Sosman JA; Ribas A J Clin Oncol; 2013 May; 31(14):1767-74. PubMed ID: 23569304 [TBL] [Abstract][Full Text] [Related]
18. Long-term vemurafenib treatment drives inhibitor resistance through a spontaneous KRAS G12D mutation in a BRAF V600E papillary thyroid carcinoma model. Danysh BP; Rieger EY; Sinha DK; Evers CV; Cote GJ; Cabanillas ME; Hofmann MC Oncotarget; 2016 May; 7(21):30907-23. PubMed ID: 27127178 [TBL] [Abstract][Full Text] [Related]
19. Cutaneous manifestations of vemurafenib therapy for metastatic melanoma. Owen JL; Lopez IE; Desai SR J Drugs Dermatol; 2015 May; 14(5):509-10. PubMed ID: 25942671 [TBL] [Abstract][Full Text] [Related]
20. Molecular and immunohistochemical analysis of BRAF gene in primary cutaneous melanoma: Discovery of novel mutations. Fatnassi-Mersni G; Arfaoui AT; Cherni M; Jones M; Zeglaoui F; Ouzari HI; Rammeh S J Cutan Pathol; 2020 Sep; 47(9):794-799. PubMed ID: 32285462 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]